Bempedoic acid Approval Status
FDA Approved: No
Generic name: bempedoic acid
Company: Esperion Therapeutics, Inc.
Treatment for: High Cholesterol, Familial Heterozygous
Bempedoic acid is a first-in-class, ATP Citrate Lyase (ACL) inhibitor in development for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
Bempedoic acid reduces cholesterol biosynthesis and lowers LDL-C by up-regulating the LDL receptor. Similar to statins, bempedoic acid also reduces hsCRP, a key marker of inflammation associated with cardiovascular disease.
Development Status and FDA Approval Process for bempedoic acid
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.